A Phase I/II, Multi-Center, Open Label Study of Melphalan, Prednisone, Thalidomide and Defibrotide in Advanced and Refractory Multiple Myeloma Patients.

Trial Profile

A Phase I/II, Multi-Center, Open Label Study of Melphalan, Prednisone, Thalidomide and Defibrotide in Advanced and Refractory Multiple Myeloma Patients.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 12 May 2016

At a glance

  • Drugs Defibrotide (Primary) ; Melphalan; Prednisone; Thalidomide
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 09 May 2016 Status changed from discontinued to completed.
    • 15 Sep 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 09 Mar 2010 Planned end date (Oct 2006) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top